SCHEMBL19478198

SCHEMBL19478198

CCn1cc(I)nn1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16814737 0.82 — —
SCHEMBL19591091 0.79 SMPD1 (0.44) —
SCHEMBL19368290 0.78 — —
SCHEMBL24754053 0.76 SMPD1 (0.53) —
SCHEMBL2680263 0.73 — —
SCHEMBL764212 0.73 — —
SCHEMBL15509215 0.73 — —
SCHEMBL13872397 0.71 CYP19A1 (0.42) —
SCHEMBL21524613 0.71 — —
SCHEMBL9285404 0.71 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10329352-B2 Pyrrolobenzodiazepines and targeted conjugates SEATTLE GENETICS, INC. (US) 2019-06-25 — — US disclosed
WO-2019048881-A1 OLIGONUCLEOTIDES COMPRISING TRIAZOLE AND (PHOSPHOR)AMIDATE INTERNUCLEOSIDE LINKAGES, METHOD FOR THE PREPARATION AND USES THEREOF OXFORD UNIVERSITY INNOVATION LIMITED (GB) 2019-03-14 — — WO disclosed
US-20180092986-A1 SITE-SPECIFIC ANTIBODY-DRUG CONJUGATES MEDIMMUNE LIMITED (GB) 2018-04-05 — — US disclosed
EP-3134520-B1 PROCESS FOR THE MODIFICATION OF A GLYCOPROTEIN USING A GLYCOSYLTRANSFERASE THAT IS OR IS DERIVED FROM A (1,4)-N-ACETYLGALACTOSAMINYLTRANSFERASE SYNAFFIX BV (NL) 2017-12-20 — — EP disclosed
US-20170298137-A1 PYRROLOBENZODIAZEPINES AND TARGETED CONJUGATES SEAGEN INC. 2017-10-19 — — US disclosed
Send feedback